bioSyntagma is a company specializing in predictive analytics and biomarker discovery. It develops Molecular Fingerprint (mPrint) platform that creates a multi-omic and spatial profile of tissue to get a complete and informed understanding of the patient’s cancer so they can be matched with relevant therapies and recommended course of actions that prevent acquired drug resistance.